These results suggest that the SGK/NF-κB signaling pathway contributes to a low sensitivity to bortezomib and ixazomib and an SGK or NF-κB inhibitor may enhance the cytotoxic effect of bortezomib and ixazomib in MM cells. Here, NFKB1 is linked to Miyoshi myopathy.